# Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

> **NCT00856297** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 389 (actual)

## Conditions studied

- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** MenACWY-CRM conjugate vaccine
- **BIOLOGICAL:** Licensed comparator

## Key facts

- **NCT ID:** NCT00856297
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 389 (ACTUAL)
- **Last updated:** 2017-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00856297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00856297, "Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00856297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*